Biotech Values

[jq1234]

This is just one of many articles on AZN's shifting position on biosimilar/biobetter. The point is AZN wants to get into FoB, but not sure exactly how. To me, MNTA is more likely to partner with someone who doesn't have firm established FoB programs (SNY, AZN, LLY etc) than those with more established programs if MNTA is seeking the strategic term they say they are seeking IMO.